Login to Your Account

Zybrestat's Phase II Ovarian Cancer Trial Passes Review

By Catherine Shaffer
Staff Writer

Friday, February 8, 2013
Shares of OxiGene Inc. bounced 14.8 percent Thursday on news that its Phase II study of Zybrestat and Avastin in ovarian cancer demonstrated acceptable tolerability in an interim toxicity analysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription